SpyGlass Pharma, Inc. (SGP) SEC Filings, Feb 5, 2026

SpyGlass Pharma, Inc. director and Chief Executive Officer Patrick H. Mooney filed an initial ownership report, showing his beneficial holdings in the company. He directly owns 183,153 shares of common stock and holds several stock options to acquire additional common shares at exercise prices ranging from $0.35 to $7.11, with expiration dates extending to 2035. The options generally vest over four years, with 25% vesting after one year from each grant’s vesting commencement date and the remainder vesting monthly, contingent on his continued service to the company.